Monte Rosa's MRT-8102 faces H2 test to confirm 85% CRP cut in more patients
GFORCE-1's expanded cohort will show whether the oral NEK7 degrader's interim CRP reduction holds as Monte Rosa readies a Phase 2 ASCVD study.
Executive Summary
- Monte Rosa Therapeutics is preparing to disclose expanded Phase 1 data on its oral NEK7-degrader in patients with elevated cardiovascular risk, building on an interim readout that already showed an 85% CRP reduction.
- The trial's status moved to active and not recruiting as enrollment closed, and its registered completion date now aligns with the guidance the company has repeated since January, rather than reflecting a new delay.
- Because the sponsor already reported an outsized inflammatory-marker reduction in the small interim cohort, the expanded readout's job is to show that result holds across a broader dose range and more participants, not to establish a first signal.
- No other industry trial pairs the NEK7 target with this cardiovascular-risk population, leaving the asset without a direct precedent to benchmark against inside its own mechanism class.
The catalyst
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is running GFORCE-1, a first-in-human, three-part Phase 1 study of MRT-8102 in healthy volunteers and participants with elevated cardiovascular risk and elevated C-reactive protein, or CRP, a marker of systemic inflammation. The company has told investors three times since January, most recently in a first-quarter 2026 update, that it expects additional data from the study in the second half of 2026. The trial has expanded to include multiple dose levels in its at-risk cohort, a change the company said was intended to accelerate development toward a Phase 2 study in atherosclerotic cardiovascular disease, or ASCVD. NCT07119125+1A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPNCT07119125Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating ...Jan 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the interim data showed
In an interim readout disclosed on January 7, 2026, Monte Rosa reported that after four weeks of dosing, MRT-8102 reduced median high-sensitivity CRP levels by 85%, and that 94% of participants reached CRP below 2 mg/L, a threshold the company linked to reduced cardiovascular risk. That result came despite a median baseline CRP of 6.3 mg/L, which the company said ran higher than levels seen in benchmark trials. Chief Executive Officer Markus Warmuth said the reduction was "comparable to those previously reported with biologic therapies" for an oral molecular glue degrader. Single and multiple ascending dose cohorts, spanning 5 mg to 400 mg daily, showed NEK7 degradation at all dose levels tested and reductions in interleukin-1-beta and interleukin-6 at all dose levels tested, with mild to moderate adverse events and no signal of increased infection risk. MonteMonte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating ...Jan 7, 2026
Trial mechanics
GFORCE-1 targets 100 participants and moved to active, not recruiting status as of June 4, 2026, when its registered primary completion date shifted from January 1, 2026 to July 1, 2026. That six-month shift lines up with the H2-2026 readout window the company had already guided to in January, March and May disclosures, so it reads as a registry update catching up to standing guidance rather than a new slip. The trial's own primary endpoints are safety and tolerability across its single-dose, multiple-dose, and 28-day dosing cohorts in the elevated-CRP population, not an efficacy endpoint. The study carries a randomized, placebo-controlled design with three primary and nine secondary endpoints, most of the latter tracking pharmacokinetics. NCT07119125+1A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPNCT07119125Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating ...Jan 7, 2026
Competitive frame
MRT-8102 has no direct comparator sharing both its NEK7 target and its cardiovascular-risk population; the closest same-target trial found is a Phase 1 hepatocellular carcinoma study in France, Spain and Germany from a different sponsor, and the closest same-indication trials in the cardiovascular-risk landscape run through cholesterol- and lipoprotein-lowering mechanisms such as statins, PCSK9 inhibitors and lipoprotein(a)-targeting therapies, none of which share MRT-8102's inflammatory pathway. That leaves the NEK7-directed molecular glue mechanism without a validated precedent in this setting: the informative outcome for the expanded readout is whether the CRP reduction already shown in the small interim cohort extends across the added dose levels and larger participant count, since that is the evidence the company needs to carry into a planned Phase 2 ASCVD study.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.